Honest Company Inc vs Mesoblast Limited — how do they compare? Honest Company Inc trades at $5.09 (market cap $558.95M), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 4× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| HNST | MESO | |
|---|---|---|
Market Cap | $558.95M | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $5.46 | $20.96 |
52-Week Low | $2.10 | $12.88 |
Enterprise Value | $462.56M | $2.21B |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.065, down 3.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue due to strategic exits. Despite negative net income margins and ROE, cash flow improved significantly in 2025 with $14.15M net cash flow. Analyst consensus shows 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious as strategic exits pressure revenue while cost improvements support margins. Investment opportunity exists if profitability targets are met, but risks include persistent net losses and competitive pressures in personal care markets. The stock's elevated P/E ratio of 48.83 requires careful valuation assessment.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Trailing returns across standard periods
Latest headlines on both assets
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →